Drugs / Recombinant protein antigen (rPA)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00133484 | ? → May 2007 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant protein antigen (rPA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00133484 ↗ |
| Modality | Vaccine | “3 Recombinant Protective Antigen (rPA) Anthrax Vaccines” NCT00133484 ↗ |
| Route | Intramuscular | “2-dose regimens of 100 g rPA vaccines (3 products) administered by the intramuscular (IM) route” NCT00133484 ↗ |